Table 3.

Participant Disposition Through Week 48

Disposition	D/C/F/TAF (N = 109)
Completed	97 (89)
Discontinueda	12 (11)
Baseline resistance	0 (0)
Safety stopping rules	3 (3)
Adverse event	1 (<1)
Lost to follow-up	4 (4)
Protocol violation	1 (<1)
Withdrawal of consent	1 (<1)
Otherb	2 (2)

Data are presented as no. (%).

Abbreviations: D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide.

^aOf the 11 participants who prematurely discontinued treatment, retention in care assessment was completed for 7 (64%) participants; among these participants, 6 (86%) had a documented clinical visit within 90 days of discontinuing D/C/F/TAF. One participant withdrew consent and no follow-up effort was made, while 1 participant was lost to follow-up (the site attempted a follow-up that yielded no information [failed attempt]).

^bOther reasons were participant incarceration and switch to another antiretroviral due to D/C/F/TAF food requirements.